Skip to main content
SpringerLink
Log in

Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The objective of this study was to compare the effectiveness of the low molecular weight heparin, enoxaparin (Lovenox®), and inogatran (a direct thrombin inhibitor) in a canine electrolytic injury model of venous thrombosis. Effectiveness was defined as the ability of either drug to prolong the following parameters: activated partial thromboplastin time (aPTT), thrombin time (TT), prothrombin time (PT), and time to formation of an occlusive thrombus in the vein. There were 5 dogs and 10 vessels for each group (the right and left femoral veins were used in each dog to measure time to occlusion). Dogs were randomly assigned to one of six groups: (1) saline controls; (2) low-dose inogatran (0.075 mg/kg IV bolus followed by a 5 μg/kg/min infusion); (3) mid-dose inogatran (0.25 mg/kg IV bolus followed by a 20 μg/kg/min infusion); (4) high-dose inogatran (0.75 mg/kg IV bolus followed by a 50 μg/kg/min infusion); (5) low-dose enoxaparin (100 units/kg IV bolus followed by a 50 U/kg/h infusion); and (6) high-dose enoxaparin (200 U/kg IV bolus followed by a 100 U/kg/h infusion). Administration of inogatran resulted in dose-dependent increases in aPTT, TT, and PT, and administration of enoxaparin resulted in dose-dependent increases in aPTT and TT. There were no changes in hemodynamics. The time to occlusion in the control group averaged 81.7 ± 9.9 minutes compared with 141.8 ± 12.7, 185.8 ± 17.6, and 226.9 ± 8.8 minutes with the low, mid, and high doses of inogatran, and 131 ± 20.3, and 183.0 ± 19.0 minutes with the low and high doses of enoxaparin. Bleeding times were elevated by inogatran and enoxaparin, but no appreciable differences were detected between the two compounds. In summary, the direct thrombin inhibitor inogatran, administered intravenously, was as effective as the low molecular weight heparin enoxaparin in a canine model of venous thrombosis induced by electrolytic injury, supporting the conclusion that direct antithrombins may prove useful for prevention and treatment of deep venous thrombosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haines ST, Bussey HI. Thrombosis and the pharmacology of antithrombotic agents. Ann Pharmacother 1995;29:892–905.

    PubMed  Google Scholar 

  2. Anderson-FA J, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933–938.

    PubMed  Google Scholar 

  3. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3 ed. Philadelphia: JB Lippincott, 1994:1275–1296.

    Google Scholar 

  4. Clagett GP, Anderson-FA J, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism [see comments]. Chest 1992;102:391S–407S.

    PubMed  Google Scholar 

  5. FitzGerald GA. The human pharmacology of thrombin inhibition. Cor Art Dis 1996;7:911–918.

    Google Scholar 

  6. Weitz J. New anticoagulant strategies. Current status and future potential. Drugs 1994;48:485–497.

    PubMed  Google Scholar 

  7. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association [published erratum appears in Circulation 1995 91:A55–A56]. Circulation 1994;89:1469–1480.

    Google Scholar 

  8. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: Molecular design and pharmacological profile Trends Pharmacol Sci 1993;14:366–376.

    PubMed  Google Scholar 

  9. Hirsh J. Low molecular weight heparin. Thromb Haemost 1993;70:204–207.

    PubMed  Google Scholar 

  10. Carter CA, Skoutakis VA, Spiro TE, et al. Enoxaparin: The low-molecular-weight heparin for prevention of postoperative thromboembolic complications [see comments]. Ann Pharmacother 1993;27:1223–1230.

    PubMed  Google Scholar 

  11. Verstraete M. Direct thrombin inhibitors: Appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997;78:357–363.

    PubMed  Google Scholar 

  12. Philippides GJ, Loscalzo J. Potential advantages of directacting thrombin inhibitors. Cor Art Dis 1996;7:497–507.

    Google Scholar 

  13. Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res 1997; 85:133–145.

    PubMed  Google Scholar 

  14. Gustafsson D, Elg M. Lenfors S, Borjesson I, Teger NA. Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolys 1996;7:69–79.

    Google Scholar 

  15. Buckley MM, Sorkin EM. Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44: 465–497.

    PubMed  Google Scholar 

  16. Cosmi B, Hirsh J. Low molecular weight heparins. Curr Opin Cardiol 1994;9:612–618.

    PubMed  Google Scholar 

  17. Noble S, Peters DH, Goa KL. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49:388–410.

    PubMed  Google Scholar 

  18. Haas S. The role of low-molecular-weight heparins in the prevention of venous thrombosis in surgery with special reference to enoxaparin. Haemostasis 1996;26(Suppl. 2): 39–48.

    PubMed  Google Scholar 

  19. Eriksson BI, Wille JP, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement [see comments]. N Engl J Med 1997;337: 1329–1335.

    PubMed  Google Scholar 

  20. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin,CGP39393 [see comments]. Lancet 1996;347:635–639.

    PubMed  Google Scholar 

  21. Uriuda Y, Wang QD, Grip L, Ryden L, Sjoquist PO, Mattsson C. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closedchest porcine model of coronary artery thrombosis. Cardiovasc Res 1996;32:320–327.

    PubMed  Google Scholar 

  22. Finkle CD, St. Pierre A, Leblond L, Deschenes I, DiMaio J, Winocour PD. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis—comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost 1998;79:431–438.

    PubMed  Google Scholar 

  23. Preville P, He J, Tarazi M, Siddiqui M, Cody W, Doherty A. An efficient preparation of the potent and selective pseudopeptide thrombin inhibitor, inogatran. Bioorg Med Chem Lett 1997;7:1563–1566.

    Google Scholar 

  24. Carter CJ. New developments in acute anticoagulation therapy: What improvements over traditional heparin are on the horizon? Postgrad Med 1996;99:129–136.

    PubMed  Google Scholar 

  25. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816–1828.

    PubMed  Google Scholar 

  26. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330–334.

    PubMed  Google Scholar 

  27. Agnelli G, Iorio A, Renga C, et al. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995;92:2819–2824.

    PubMed  Google Scholar 

  28. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-venin thrombosis. Lancet 1992;339:441–445.

    PubMed  Google Scholar 

  29. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis [see comments]. Arch Intern Med 1995;155:601–607.

    PubMed  Google Scholar 

  30. Goldhaber SZ. Practical aspects of venous thromboembolism prevention: An overview. Cardiovascular Reviews & Reports 1994;15(12):34–44.

    Google Scholar 

  31. Mousa SA, Mu DX, Lucchesi BR. Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs. Stroke 1997;28:830–835.

    PubMed  Google Scholar 

  32. Sudo Y, Lucchesi BR. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: A comparison with heparin. J Cardiovasc Pharmacol 1996; 27:545–555.

    PubMed  Google Scholar 

  33. Rebello SS, Miller BV, Basler GC, Lucchesi BR. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol 1997;29:240–249.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vascular and Cardiac Diseases Section, and Biometrics Section, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, Michigan, USA

    Diane P. Ignasiak, Thomas B. McClanahan, Richard E. Bousley, Paul L. Juneau & Kim P. Gallagher

Authors
  1. Diane P. Ignasiak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas B. McClanahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard E. Bousley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul L. Juneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kim P. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ignasiak, D.P., McClanahan, T.B., Bousley, R.E. et al. Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog. J Thromb Thrombolysis 6, 199–206 (1998). https://doi.org/10.1023/A:1008806312396

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008806312396

Search

Navigation